The final results of the European Randomized Study of Screening for Prostate Cancer (ERSPC), following participants for 23 years, demonstrate that sustained, protocol-driven prostate-specific antigen (PSA) screening lowers prostate cancer mortality and improves the balance between benefits and harms. These findings advocate for risk-based, patient-centered screening strategies that optimize early detection while minimizing unnecessary interventions.
The ERSPC trial, published recently in The New England Journal of Medicine, represents one of the longest and largest randomized screening studies for prostate cancer to date. Conducted across eight European countries, the study enrolled men aged 55 to 69 and compared repeated PSA-based screening invitations with no screening. The goal was to evaluate the long-term impact of PSA screening on prostate cancer deaths and to assess the potential harms of overdiagnosis and overtreatment.
Balancing Benefits and Risks in Prostate Cancer Screening
Prostate cancer is among the leading causes of cancer death in men, especially in aging populations. PSA testing provides an opportunity for earlier detection, which can subsequently reduce mortality. However, PSA-based screening carries risks, including false positives, unnecessary biopsies, and the treatment of tumors unlikely to cause harm during a man’s lifetime. Overdiagnosis can lead to anxiety and medical interventions without clear benefit. Given the aging population and rising incidence of prostate cancer globally, health systems face the challenge of maximizing mortality reduction while minimizing impacts on quality of life and resource use.
Study Design and Methods
The ERSPC randomized men into a screening arm invited for periodic PSA testing and a control arm with no invitation to screening. Screening intervals varied by country from two to seven years, with biopsies recommended if PSA levels surpassed 3.0 ng/mL, supported by ancillary tests in borderline cases. The primary outcome assessed was prostate cancer mortality adjudicated by blinded committees. Secondary outcomes included cancer incidence by disease risk categories and rates of metastatic disease. The analysis accounted for deaths from other causes to ensure precise mortality assessment attributable to prostate cancer.
Key Long-Term Outcomes
After a median follow-up of 23 years, the ERSPC demonstrated a 13% relative reduction in prostate cancer mortality in the screened group compared to controls (rate ratio 0.87). This corresponded to an absolute risk reduction of 0.22%, meaning that inviting 456 men to screening prevented one death from prostate cancer, while diagnosing 12 men prevented one death. Notably, all-cause mortality remained similar between groups, emphasizing that life expectancy influences the net benefits of screening.
Shift Toward Early Detection and Reduced Advanced Disease
Screening increased prostate cancer diagnosis rates by 30%, primarily due to detection of more low-risk tumors. Importantly, the incidence of advanced disease was reduced by 34%, confirming that PSA screening shifts diagnosis toward earlier, less aggressive cancers. High compliance rates—with 83% participation in at least one screening round and 89% biopsy adherence—underscore the feasibility of sustained program delivery.
Improved Harm-Benefit Ratio Over Time
Compared with earlier reports, the long-term data show an improved benefit-to-harm ratio. While screening detected additional cancers (some indolent), the number of men needing treatment to prevent one prostate cancer death decreased from 18 to 12 over time. This reduction reflects advances in risk stratification and the natural history of screen-detected cancers. Furthermore, mortality benefit persisted for years after screening ended, although diminishing benefits were observed beyond six years in men with competing age-related mortality risks.
Comparison with Other Major Screening Trials
ERSPC results contrast with the U.S. PLCO trial, where widespread opportunistic PSA testing in the control arm diluted observed mortality differences, and the U.K. CAP trial, which had only a single screening invitation with lower participation. These comparisons highlight the importance of repeated, protocolized screening and high engagement to achieve meaningful mortality reductions. They align with expert consensus favoring organized screening programs over opportunistic or one-off testing.
Towards Risk-Based, Individualized Screening
Current evidence supports transitioning from uniform PSA screening to tailored approaches considering individual risk factors, such as baseline PSA levels, age, family history, and genetic predisposition. Integration of magnetic resonance imaging (MRI) and novel biomarkers can improve identification of clinically significant cancers and reduce unnecessary biopsies and treatments. Active surveillance is increasingly recommended for low-risk tumors to avoid overtreatment and associated side effects.
Public Health and Clinical Implications
Prostate cancer screening programs should implement risk-adapted screening intervals and consider stopping screening in men with very low midlife PSA levels or limited life expectancy, optimizing resource allocation and patient outcomes. The ERSPC’s long-term findings furnish high-quality evidence for informed shared decision-making between men and their healthcare providers, ensuring that screening benefits align with individual values and health priorities.
Overall, these findings mark an important step in refining prostate cancer screening to save lives while minimizing harms, supporting international public health strategies for cancer prevention and early detection. According to experts from Science Media Centre and key researchers, this evidence will inform screening guidelines globally, highlighting the potential to integrate PSA testing with modern imaging and genetic tools for precision screening.
Read more on Globally Pulse Health.
